Currently Viewing:
World Health Care Congress 2019
Unlocking Innovation in Value-Based Care
April 29, 2019
In First Speech Since Stepping Down as FDA Commissioner, Gottlieb Reflects on Agency's Push for Innovation
April 30, 2019
The Intersection of Technology and Care Management: Ensuring Optimal Aging at Home
April 30, 2019
Building the Evidence Base to Quantify, Communicate the ROI of SDOH Initiatives
April 30, 2019
Currently Reading
Senator Cassidy Touts Alternative to Medicare for All, Outlines Other Healthcare Priorities
May 01, 2019
Dr Martin Makary Discusses Hospitals Being Required to Post Prices of Services Online
May 09, 2019
Dr Susan Mani: How LifeBridge Health Came to Recognize the Importance of SDOH
May 17, 2019
Dr Martin Makary on How PBMs Impact Drug Pricing, Transparency
May 20, 2019
Dr Jason Mitchell: How Freestanding EDs Can Be Utilized in Shift to Value-Based Care
May 22, 2019
Dr Susan Mani Outlines Barriers to Understanding the ROI of SDOH Initiatives
May 31, 2019
Dr Martin Makary Outlines Advantages, Disadvantages of Group Purchasing Organizations
June 02, 2019
Dr Jason Mitchell on Aligning Incentives Across the Entire Healthcare System
June 05, 2019
Dr Susan Mani: How to Ensure Scalability, Sustainability of SDOH Initiatives
June 11, 2019
Dr Jason Mitchell Discusses Which Payment Models Have the Most Potential
June 17, 2019
Dr Jason Mitchell: Think Beyond a Patient's Disease Process
June 30, 2019
Dr Jason Mitchell Details the Importance of Data in Value-Based Care
July 11, 2019
Dr Jason Mitchell Outlines the Role of Commercial Payers in Value-Based Care
July 20, 2019

Senator Cassidy Touts Alternative to Medicare for All, Outlines Other Healthcare Priorities

Jaime Rosenberg
During a session at World Health Care Congress 2019, Senator Bill Cassidy, MD, offered his alternative to Medicare for All, which is modeled after the Children’s Health Insurance Program, and discussed other healthcare issues on his radar.
During a session at World Health Care Congress 2019, Senator Bill Cassidy, MD, criticized the idea of Medicare for All, arguing that the move would give government power over the patient rather than give patients power over their healthcare. Offering an alternative, Cassidy, R-Lousiana, outlined his vision for allowing states to offer healthcare to their specific populations.

Modeled after the Children’s Health Insurance Program, which is funded jointly by states and the federal government, the plan would move away from a flat rate per patient. Instead, said Cassidy, the federal government would look at a state’s expansion population and individual exchanges and offer adjusted rates based on the health status and demographics of the population. For example, he said, women who are 50 would be cheaper than men who are 50, and children would be cheaper than adults. From there, states would be held accountable for outcomes.

In addition to an alternative to Medicare for All, Cassidy has set a focus on surprise medical billing and price transparency, which has gained support from both sides of the aisle. “You can’t live in our society without being impacted by costs by one way or another,” he said.

He added: “If you have a patient that goes to an in-network hospital, she should not get an out-of-network bill. Nor should she be the point of leverage as the provider and insurer duke it out over how much they should get paid.”

On the point of price transparency, Cassidy noted the administration’s barring of the so-called pharmacist gag clause and envisioned the ability for a patient to be able to scan a quick response code and look up rates of a service throughout the area. He referenced a Los Angeles Times article that unearthed a difference of more than $2000 for the same service within the same area code.

“The only way you knew that was if you were an investigative reporter for the LA Times. That should not be the case,” he said.

Unsurprisingly, the issue of rising drug costs also came to the forefront of the discussion, with Cassidy using emerging gene therapies as an example. We currently have a pricing system where the list price is set by the drug company with no pushback, he said. As a result, gene therapies are being priced at a point where few can afford it, highlighting the need to find a balance between promoting innovation and making up for research costs and ensuring drug competition.

Looking toward Germany, Cassidy explained that the country allows the opening price of a drug to be set by the drug company and after 3 months, there is an analysis of the benefits of the drug and whether the benefits support its price. Analyses from manufacturers, insurers, and other stakeholders are taken into consideration by an arbitrator who determines the value.

“It gives a reward for innovation and the ability to build your case empirically, but if it’s way overpriced, there will be some correction on the backside,” he said.

And this isn’t needed just for first-in-class novel therapies; it’s also needed for generics, said Cassidy, referencing tactics that drug companies use to block generic drug competition when their drug goes off patent. 

Although he is a proponent of the International Pricing Index, which would allow Medicare to determine the price it pays for certain drugs based on the prices that other countries pay, Cassidy said he would be open to other ideas if they could address rising drug costs.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up